• 1
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314319.
  • 2
    Legros B, Boon P, De Jonghe P, et al. Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2). Acta Neurol Scand 2009;120:402410.
  • 3
    St Louis EK, Gidal BE, Henry TR, et al. Conversions between monotherapies in epilepsy: expert consensus. Epilepsy Behav 2007;11:222234.
  • 4
    Somerville ER. Some treatments cause seizure aggravation in idiopathic epilepsies (especiallyabsence epilepsy). Epilepsia 2009;50(Suppl. 8):3136.
  • 5
    Sazgar M, Bourgeois BF.Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 2005;33:227234.
  • 6
    Somerville ER. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 2002;59:7983.
  • 7
    Yang MT, Lee WT, Chu LW, et al. Anti-epileptic drugs-induced de novo absence seizures. Brain Dev 2003;5:5156.
  • 8
    Brodie MJ, Sills GJ. Combining antiepileptic drugs–rational polytherapy? Seizure 2011;20:369375.
  • 9
    Sake JK, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:10551068.
  • 10
    Angehagen M, Margineanu DG, Ben-Menachem E, et al. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. NeuroReport 2003;14(3):471475.
  • 11
    Löscher W, Hönack D, Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Bin Res 2003;735:208216.
  • 12
    Sitges M, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacology 2007;53:854862.
  • 13
    Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res 1997;26:423432.
  • 14
    Lindberger M, Alenius M, Frisén L, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in refractory epilepsy add-on treatment. Epilepsia 2000;41:12891295.
  • 15
    Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010;51:726.
  • 16
    Glauser T, Ben-Menachem E, Bourgeois B. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551563.
  • 17
    French JA, Kanner AM, Bautista J, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:12611273.
  • 18
    Arroyo S. Rufinamide. Neurotherapeutics 2007;1:155162.
  • 19
    Pålhagen S, Canger R, Henriksen O, et al. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001;43:115124.
  • 20
    Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurotherapeutics 2007;1:145148.
  • 21
    Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13:2142.
  • 22
    Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:13081317.
  • 23
    Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443453.
  • 24
    Novy J, Bartolini E, Bell GS, et al. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation. Epillepsy Res 2013;106:250256.
  • 25
    Kellinghaus C, Berning S, Stögbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand 2013 Aug 13 [E-pub ahead of print].
  • 26
    Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand Suppl 2011;192:515.
  • 27
    Willmore LJ, Abelson MB, Ben-Menachem E, et al. Vigabatrin: 2008 update. Epilepsia 2009;50:163173.
  • 28
    Pellock JM. Balancing clinical benefits of vigabatrin with its associated risk of vision loss. Acta Neurol Scand Suppl 2011;192:8391.
  • 29
    Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl 2013;197:38.
  • 30
    Gidal BE, Ferry J, Majid O, et al. Concentration–effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 2013;54:14901497.
  • 31
    Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 2012;53:935946.
  • 32
    Gil-Nagel A, Elger C, Ben-Menachem E. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind ohase III clinical studies. Epilepsia 2013;54:98107.
  • 33
    Martyn-St James M, Glanville J, McCool R, et al. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Seizure 2012;21:665678.
  • 34
    Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012;53:412424.
  • 35
    Orhan G, Wuttke TV, Nies AT, et al. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin Pharmacother 2012;13:18071816.
  • 36
    Rheims S, Ryvlin P. Retigabine for partial onset seizures. Expert Rev Neurother 2012;12:509517.
  • 37
    Faulkner MA, Burke RA. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Expert Opin Drug Saf 2013;12:847855.